Strive, Inc 10-Q for FY2026 Q2

Strive, Inc. (ASST)

10-Q 2026-08-10 For: 2026-06-30

Added on August 10, 2026

About this 10-Q

Strive, Inc filed this 10-Q on August 10, 2026, covering the quarter ended June 30, 2026 (FY2026 Q2).

Headline figures

Quarter ended June 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $2.94M; up 94.6% from $1.51M a year earlier
Net loss: $257.6M; compared with a net loss of $8.88M a year earlier
Diluted EPS: -$3.77; compared with -$3.86 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Nevada	001-41612	88-1293236
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

200 Crescent Ct., Suite 1400, Dallas, Texas 75201
(Address of principal executive offices and zip code)


		Page
PART I.	FINANCIAL INFORMATION	1

Item 1.	Consolidated Financial Statements	1
	Consolidated Statements of Financial Condition as of June 30, 2026 (unaudited) and December 31, 2025 (audited)	1
	Consolidated Statements of Operations (unaudited) for the Three Months Ended June 30, 2026 (Successor) and 2025 (Predecessor)	2
	Consolidated Statements of Operations (unaudited) for the Six Months Ended June 30, 2026 (Successor) and 2025 (Predecessor)	3
	Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Six Months Ended June 30, 2026 (Successor) and 2025 (Predecessor)	4
	Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2026 (Successor) and 2025 (Predecessor)	5
	Notes to Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33

Item 4.	Controls and Procedures	34

PART II.	OTHER INFORMATION	35

Item 1.	Legal Proceedings	35

Item 1A.	Risk Factors	35

Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities	35

Item 3.	Defaults Upon Senior Securities	35

Item 4.	Mine Safety Disclosures	35

Item 5.	Other Information	35

Item 6.	Exhibits	36


	June 30, 2026		December 31, 2025
	(unaudited)		(audited)
Assets:
Current assets:
Cash and cash equivalents	$	145,466	$	67,499
Investments in preferred equity, at fair value	42,854		—
Prepaid expenses	2,018		2,708
Other current assets	2,231		1,569
Total current assets	192,569		71,776
Digital assets, at fair value	1,164,639		668,486
Property and equipment, net	798		778
Intangible assets, net	14,982		355
Right-of-use lease assets	3,825		4,037
Other non-current assets	296		95
Total assets	$	1,377,109	$	745,527

Liabilities:
Current liabilities:
Compensation and benefits payable	$	9,624	$	164
Accounts payable and other liabilities	7,146		8,560
Dividends payable	8,492		2,053
Total current liabilities	25,262		10,777
Operating lease liabilities	3,319		3,512
Total liabilities	28,581		14,289

Mezzanine equity:
Variable Rate Series A Preferred Stock, $0.001 par value; 40,000,000 and 20,000,000 shares authorized, 7,829,502 and 2,012,729 shares issued and outstanding, $783.0 million and $201.3 million redemption value and liquidation preference as of June 30, 2026 and December 31, 2025, respectively	702,373		148,802
Total mezzanine equity	702,373		148,802

Stockholders’ equity:
Class A common stock, $0.001 par value; 22,200,000,000 shares authorized, 72,164,809 and 34,936,745 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	72		699
Class B common stock, $0.001 par value; 1,050,000,000 shares authorized, 9,780,018 and 9,776,540 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	10		196
Additional paid-in capital	1,683,299		1,055,595
Accumulated deficit	(1,037,226)		(474,054)
Total stockholders’ equity	646,155		582,436
Total liabilities, mezzanine equity, and stockholders' equity	$	1,377,109	$	745,527


	Successor		Predecessor
	Three Months Ended June 30, 2026		Three Months Ended June 30, 2025
Revenues:
Investment advisory fees	$	1,512	$	1,488
Medical device revenues	1,388		—
Other revenue	41		23
Total revenues	2,941		1,511

Operating expenses:
Fund management and administration	1,489		1,588
Employee compensation and benefits	16,314		2,005
General and administrative expense	6,428		1,452
Marketing and advertising	79		102
Depreciation and amortization	86		54
Total operating expenses	24,396		5,201

Investment losses:
Net unrealized loss on digital assets, at fair value	(228,031)		—
Net unrealized loss on investments in preferred equity, at fair value	(5,962)		—
Other investment loss	(2,801)		—
Total investment losses	(236,794)		—

Net operating loss	(258,249)		(3,690)

Other income/(expense):
Other income	955		252
Interest expense on long-term notes payable, at fair value	(40)		—
Change in fair value on long-term notes payable, at fair value	(299)		—
Gain on extinguishment of debt	30		—
Transaction costs	—		(5,437)
Total other income/(expense)	646		(5,185)

Net loss before income taxes	(257,603)		(8,875)
Income tax benefit/(expense)	—		—
Net loss	$	(257,603)	$	(8,875)
Dividends on preferred stock	(26,209)		—
Net loss attributable to common stockholders	$	(283,812)	$	(8,875)

Weighted average number of common shares outstanding:
Basic (1)	75,275,806		2,300,998
Diluted (1)	75,275,806		2,300,998

Net loss per common share:
Basic (1)	$	(3.77)	$	(3.86)
Diluted (1)	$	(3.77)	$	(3.86)


	Successor		Predecessor
	Six Months Ended June 30, 2026		Six Months Ended June 30, 2025
Revenues:
Investment advisory fees	$	2,859	$	2,904
Medical device revenues	2,758		—
Other revenue	84		30
Total revenues	5,701		2,934

Operating expenses:
Fund management and administration	2,913		2,999
Employee compensation and benefits	29,367		4,071
General and administrative expense	12,366		3,358
Marketing and advertising	195		163
Depreciation and amortization	176		106
Total operating expenses	45,017		10,697

Investment losses:
Net unrealized loss on digital assets, at fair value	(523,809)		—
Net unrealized loss on investments in preferred equity, at fair value	(5,472)		—
Other investment loss	(2,801)		—
Total investment losses	(532,082)		—

Net operating loss	(571,398)		(7,763)

Other income/(expense):
Other income	1,481		576
Interest expense on long-term notes payable, at fair value	(282)		—
Change in fair value on long-term notes payable, at fair value	(2,464)		—
Loss on extinguishment of debt	(8,431)		—
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan	(2,594)		—
Transaction costs	(6,525)		(5,437)
Bargain purchase gain	66,704		—
Total other income/(expense)	47,889		(4,861)

Net loss before income taxes	(523,509)		(12,624)
Income tax benefit/(expense)	—		—
Net loss	$	(523,509)	$	(12,624)
Dividends on preferred stock	(39,663)		—
Net loss attributable to common stockholders	$	(563,172)	$	(12,624)

Weighted average number of common shares outstanding:
Basic (1)	68,490,600		2,288,538
Diluted (1)	68,490,600		2,288,538

Net loss per common share:
Basic (1)	$	(8.22)	$	(5.52)
Diluted (1)	$	(8.22)	$	(5.52)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


	Predecessor
	Mezzanine Equity			Stockholders' Equity
	Successor Perpetual			Predecessor			Predecessor Class A			Predecessor Class B			Successor Class A			Successor Class B			Additional		Retained Earnings/		Total
	Preferred Stock			Preferred Stock			Common Stock			Common Stock			Common Stock			Common Stock			Paid-in		(Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Shares	Par Value		Shares	Par Value		Shares	Par Value		Shares	Par Value		Capital		Deficit)		Equity
Balance at December 31, 2024	—	$	—	1,158,802	$	72,488	2,000,000	$	—	400,970	$	—	—	$	—	—	$	—	$	—	$	(49,146)	$	23,342
Net loss	—	—		—	—		—	—		—	—		—	—		—	—		—		(3,749)		(3,749)
Balance at March 31, 2025	—	$	—	1,158,802	$	72,488	2,000,000	$	—	400,970	$	—	—	$	—	—	$	—	$	—	$	(52,895)	$	19,593
Net loss	—	—		—	—		—	—		—	—		—	—		—	—		—		(8,875)		(8,875)
Balance at June 30, 2025	—	$	—	1,158,802	$	72,488	2,000,000	$	—	400,970	$	—	—	$	—	—	$	—	$	—	$	(61,770)	$	10,718

	Successor
	Mezzanine Equity			Stockholders' Equity
	Successor Perpetual			Predecessor			Predecessor Class A			Predecessor Class B			Successor Class A			Successor Class B			Additional		Retained Earnings/		Total
	Preferred Stock			Preferred Stock			Common Stock			Common Stock			Common Stock			Common Stock			Paid-in		(Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Shares	Par Value		Shares	Par Value		Shares	Par Value		Shares	Par Value		Capital		Deficit)		Equity
Balance at December 31, 2025	2,012,729	$	148,802	—	$	—	—	$	—	—	$	—	34,936,745	$	699	9,776,540	$	196	$	1,055,595	$	(474,054)	$	582,436
Adjustment of par value as a result of reverse stock split	—	—		—	—		—	—		—	—		—	(664)		—	(186)		850		—		—
Business combination with Semler Scientific, Inc.	—	—		—	—		—	—		—	—		16,090,786	16		—	—		311,167		—		311,183
Share-based compensation expense	—	—		—	—		—	—		—	—		—	—		—	—		6,529		—		6,529
Issuance of Class A common stock	—	—		—	—		—	—		—	—		8,182,150	8		—	—		94,945		—		94,953
Issuance of common stock upon vesting of restricted stock, net of withholding taxes	—	—		—	—		—	—		—	—		—	—		118,950	—		(388)		—		(388)
Exercise of warrants	—	—		—	—		—	—		—	—		53,614	—		—	—		—		—		—
Conversions of Class B common stock to Class A common stock	—	—		—	—		—	—		—	—		23,333	—		(23,333)	—		—		—		—
Issuance of Variable Rate Series A Perpetual Preferred Stock	2,360,465	219,905		—	—		—	—		—	—		—	—		—	—		—		—		—
Issuance costs	—	(9,533)		—	—		—	—		—	—		—	—		—	—		(570)		—		(570)
Preferred stock dividends declared	—	—		—	—		—	—		—	—		—	—		—	—		—		(13,454)		(13,454)
Net loss	—	—		—	—		—	—		—	—		—	—		—	—		—		(265,906)		(265,906)
Balance at March 31, 2026	4,373,194	$	359,174	—	$	—	—	$	—	—	$	—	59,286,628	$	59	9,872,157	$	10	1,468,128		(753,414)		$	714,783
Share-based compensation expense	—	—		—	—		—	—		—	—		—	—		—	—		5,684		—		5,684
Issuance of Class A common stock	—	—		—	—		—	—		—	—		12,756,708	13		—	—		211,282		—		211,295
Issuance of common stock upon vesting of restricted stock, net of withholding taxes	—	—		—	—		—	—		—	—		4,938	—		24,396	—		(137)		—		(137)
Conversions of Class B common stock to Class A common stock	—	—		—	—		—	—		—	—		116,535	—		(116,535)	—		—		—		—
Issuance of Variable Rate Series A Perpetual Preferred Stock	3,456,308	345,663		—	—		—	—		—	—		—	—		—	—		—		—		—
Issuance costs	—	(2,464)		—	—		—	—		—	—		—	—		—	—		(1,658)		—		(1,658)
Preferred stock dividends declared	—	—		—	—		—	—		—	—		—	—		—	—		—		(26,209)		(26,209)
Net loss	—	—		—	—		—	—		—	—		—	—			—		—		(257,603)		(257,603)
Balance at June 30, 2026	7,829,502	$	702,373	—	$	—	—	$	—	—	$	—	72,164,809	$	72	9,780,018	$	10	$	1,683,299	$	(1,037,226)	$	646,155


Net increase in cash and cash equivalents	77,967		6,460
Cash and cash equivalents, beginning of period	67,499		6,155
Cash and cash equivalents, end of period	$	145,466	$	12,615

Non-cash investing and financing activities:
Change in declared but unpaid preferred stock dividends	$	6,439	$	—
Release of bitcoin held as collateral upon extinguishment of Coinbase Loan	37,971		—
Exchange of preferred stock for extinguishment of long-term notes payable, at fair value	90,108		—
Class A common stock issued as part of business combination	311,183		—
Accrued but unpaid financing transaction costs	—		450
Assets and liabilities resulting from business combination:
Prepaid expenses	599		—
Other current assets	1,831		—
Digital assets, at fair value	444,029		—
Receivable for bitcoin collateral	37,971		—
Property and equipment, net	175		—
Intangible assets, net	14,650		—
Other non-current assets	1		—
Compensation and benefits payable	2,358		—
Accounts payable and other liabilities	13,029		—
Long-term notes payable, at fair value	89,495		—
Coinbase Loan	20,000		—


	Three Months Ended June 30, 2026		Six Months Ended June 30, 2026
Balance, beginning of period	$	929,396	$	668,486
Acquisitions	463,274		984,585
Release of bitcoin held as collateral upon extinguishment of Coinbase Loan	—		35,377
Sales	—		—
Change in fair value	(228,031)		(523,809)
Balance, end of period	$	1,164,639	$	1,164,639


	June 30, 2026		December 31, 2025
Approximate number of bitcoin held	19,864		7,627
Aggregate bitcoin cost basis	$	1,882,956	$	862,994
Aggregate bitcoin fair value	$	1,164,639	$	668,486
Weighted average acquisition cost	$	94,793	$	113,153
Fair value per bitcoin	$	58,631	$	87,650


Consideration transferred:
Strive, Inc. Class A common stock and fair value of assumed options	$	311,183
Assets acquired and liabilities assumed:
Cash and cash equivalents	3,513


	Six Months Ended June 30, 2026
Total revenues	$	6,090
Net loss	$	(524,642)


	Three Months Ended June 30, 2026		Six Months Ended June 30, 2026
Balance, beginning of period	$	50,510	$	—
Acquisitions	—		50,499
Return of capital dividends	(1,694)		(2,173)
Sales	—		—
Aggregate cost basis	$	48,816	$	48,326
Change in fair value	(5,962)		(5,472)
Balance, end of period	$	42,854	$	42,854


	Three Months Ended				Six Months Ended
	June 30, 2026		June 30, 2025		June 30, 2026		June 30, 2025
	Successor		Predecessor		Successor		Predecessor
Investment advisory fees	$	1,512	$	1,488	$	2,859	$	2,904
Medical device revenues	1,388		—		2,758		—
Other revenue	41		23		84		30
Total revenue	$	2,941	$	1,511	$	5,701	$	2,934


	STRIVE, INC.

	By:	/s/ Matthew Cole
		Matthew Cole
		Chief Executive Officer
Date: August 10, 2026
	By:	/s/ Benjamin Pham
		Benjamin Pham
		Chief Financial Officer
Date: August 10, 2026


Target Number of PSUs:			[●] (“Target PSUs”)
Maximum Number of PSUs:			200% of Target PSUs
Grant Date:			[●]
Vesting:			The PSUs under this Agreement will vest on the date that the Committee certifies the Company’s achievement of the Performance Goal (as described below) following the final day of the Performance Period (with such certification anticipated to be [_______]), subject to the Grantee’s continued service through the date that the Committee certifies the Company’s achievement of the Performance Goal (unless otherwise set forth in Section 3 of the Agreement).
Performance Period:			The Performance Period under this Agreement is the three (3)-year performance period that runs from [DATES].
Performance Goal:			The Performance Goal is set forth on Appendix 1 to Exhibit A.


	Three Months Ended June 30, 2026		Six Months Ended June 30, 2026
	PIPE Traditional Warrants	PIPE Pre-Funded Warrants	PIPE Traditional Warrants	PIPE Pre-Funded Warrants
PIPE warrants outstanding, beginning of period	531,888,702	—	531,888,702	1,072,289
Issued	—	—	—	—
Exercised	—	—	—	(1,072,289)
Expired	—	—	—	—
PIPE warrants outstanding, end of period	531,888,702	—	531,888,702	—
(1) Each warrant gives the holder the right to purchase 1/20th of a share of Class A common stock.


	Three Months Ended June 30, 2026 (Successor)
	Asset Management		Medical Device		Corporate & Other		Total Consolidated
Revenues:
Investment advisory fees	$	1,512	$	—	$	—	$	1,512
Medical device revenues	—		1,388		—		1,388
Other revenue	—		—		41		41
Total revenues	1,512		1,388		41		2,941

Operating expenses:
Fund management and administration	1,489		—		—		1,489
Employee compensation and benefits	1,535		3,671		11,108		16,314
General and administrative expense	639		2,899		2,890		6,428
Marketing and advertising	4		3		72		79
Depreciation and amortization	—		31		55		86
Total operating expenses	3,667		6,604		14,125		24,396

Investment losses:
Net unrealized loss on digital assets, at fair value	—		—		(228,031)		(228,031)
Net unrealized loss on investments in preferred equity, at fair value	—		—		(5,962)		(5,962)
Other investment loss	—		—		(2,801)		(2,801)
Total investment losses	—		—		(236,794)		(236,794)

Net operating loss	(2,155)		(5,216)		(250,878)		(258,249)


	Three Months Ended June 30, 2025 (Predecessor)
	Asset Management		Medical Device		Corporate & Other		Total Consolidated
Revenues:
Investment advisory fees	$	1,488	$	—	$	—	$	1,488
Other revenue	—		—		23		23
Total revenues	1,488		—		23		1,511

Operating expenses:
Fund management and administration	1,588		—		—		1,588
Employee compensation and benefits	1,245		—		760		2,005
General and administrative expense	514		—		938		1,452
Marketing and advertising	17		—		85		102
Depreciation and amortization	—		—		54		54
Total operating expenses	3,364		—		1,837		5,201

Investment gains/(losses):
Net unrealized loss on digital assets, at fair value	—		—		—		—
Net unrealized loss on investments in preferred equity, at fair value	—		—		—		—
Net investment gains/(losses)	—		—		—		—

Net operating loss	(1,876)		—		(1,814)		(3,690)

Other income/(expense):
Other income	21		—		231		252
Transaction costs	—		—		(5,437)		(5,437)
Total other income/(expense)	21		—		(5,206)		(5,185)

Net loss before income taxes	(1,855)		—		(7,020)		(8,875)
Income tax benefit/(expense)	—		—		—		—
Net loss	$	(1,855)	$	—	$	(7,020)	$	(8,875)


	Six Months Ended June 30, 2026 (Successor)
	Asset Management		Medical Device		Corporate & Other		Total Consolidated
Revenues:
Investment advisory fees	$	2,859	$	—	$	—	$	2,859
Medical device revenues	—		2,758		—		2,758
Other revenue	—		—		84		84
Total revenues	2,859		2,758		84		5,701

Operating expenses:
Fund management and administration	2,913		—		—		2,913
Employee compensation and benefits	2,826		8,849		17,692		29,367
General and administrative expense	1,276		5,169		5,921		12,366
Marketing and advertising	11		3		181		195
Depreciation and amortization	—		63		113		176
Total operating expenses	7,026		14,084		23,907		45,017

Investment losses:
Net unrealized loss on digital assets, at fair value	—		—		(523,809)		(523,809)
Net unrealized loss on investments in preferred equity, at fair value	—		—		(5,472)		(5,472)
Other investment loss	—		—		(2,801)		(2,801)
Total investment losses	—		—		(532,082)		(532,082)

Net operating loss	(4,167)		(11,326)		(555,905)		(571,398)

Other income/(expense):
Other income	11		475		995		1,481
Interest expense on long-term notes payable, at fair value	—		—		(282)		(282)
Change in fair value on long-term notes payable, at fair value	—		—		(2,464)		(2,464)
Loss on extinguishment of debt	—		—		(8,431)		(8,431)
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan	—		—		(2,594)		(2,594)
Transaction costs	—		—		(6,525)		(6,525)
Bargain purchase gain	—		—		66,704		66,704
Total other income/(expense)	11		475		47,403		47,889

Net loss before income taxes	(4,156)		(10,851)		(508,502)		(523,509)
Income tax benefit/(expense)	—		—		—		—
Net loss	$	(4,156)	$	(10,851)	$	(508,502)	$	(523,509)


	Six Months Ended June 30, 2025 (Predecessor)
	Asset Management		Medical Device		Corporate & Other		Total Consolidated
Revenues:
Investment advisory fees	$	2,904	$	—	$	—	$	2,904
Other revenue	7		—		23		30
Total revenues	2,911		—		23		2,934


	Successor		Predecessor		Increase (Decrease)
	Three Months Ended June 30, 2026		Three Months Ended June 30, 2025		$		%
Revenues:
Investment advisory fees	$	1,512	$	1,488	$	24	1.6	%
Medical device revenues	1,388		—		1,388		100.0	%
Other revenue	41		23		18		78.3	%
Total revenues	2,941		1,511		1,430		94.6	%

Operating expenses:
Fund management and administration	1,489		1,588		(99)		(6.2)	%
Employee compensation and benefits	16,314		2,005		14,309		713.7	%
General and administrative expense	6,428		1,452		4,976		342.7	%
Marketing and advertising	79		102		(23)		(22.5)	%
Depreciation and amortization	86		54		32		59.3	%
Total operating expenses	24,396		5,201		19,195		369.1	%

Investment losses:
Net unrealized loss on digital assets, at fair value	(228,031)		—		(228,031)		(100.0)	%
Net unrealized loss on investments in preferred equity, at fair value	(5,962)		—		(5,962)		(100.0)	%
Other investment loss	(2,801)		—		(2,801)		(100.0)	%
Total investment losses	(236,794)		—		(236,794)		(100.0)	%

Net operating loss	(258,249)		(3,690)		(254,559)		6,898.6	%

Other income/(expense):
Other income	955		252		703		279.0	%
Interest expense on long-term notes payable, at fair value	(40)		—		(40)		(100.0)	%
Change in fair value on long-term notes payable, at fair value	(299)		—		(299)		(100.0)	%
Gain on extinguishment of debt	30		—		30		100.0	%
Transaction costs	—		(5,437)		5,437		100.0	%
Total other income/(expense)	646		(5,185)		5,831		(112.5)	%

Net loss before income taxes	(257,603)		(8,875)		(248,728)		2,802.6	%
Income tax benefit/(expense)	—		—		—		—	%
Net loss	$	(257,603)	$	(8,875)	$	(248,728)	2,802.6	%
Dividends on preferred stock	(26,209)		—		(26,209)		(100.0)	%
Net loss attributable to common stockholders	$	(283,812)	$	(8,875)	$	(274,937)	3,097.9	%


Exhibit Number						Description

3.1						Amended and Restated Certificate of Designation relating to the Variable Rate Series A Perpetual Preferred Stock, as filed with the Nevada Secretary of State on May 13, 2026 (effective June 15, 2026) (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on May 14, 2026).

3.2						Certificate of Amendment to Certificate of Designation relating to the Variable Rate Series A Perpetual Preferred Stock, as filed with the Nevada Secretary of State on June 5, 2026 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on June 5, 2026).

3.3						Certificate of Amendment to Amended and Restated Certificate of Designation relating to the Variable Rate Series A Perpetual Preferred Stock, as filed with the Nevada Secretary of State on June 5, 2026 (effective June 15, 2026) (incorporated by reference to Exhibit 3.2 to the Form 8-K filed on June 5, 2026).


10.1						Amended and Restated Controlled Equity OfferingSM Sales Agreement, dated June 5, 2026, by and between Strive, Inc. and Cantor Fitzgerald & Co., Barclays Capital Inc., Clear Street LLC, The Benchmark Company, LLC, StoneX Financial Inc., B. Riley Securities, Inc., Maxim Group LLC and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 5, 2026).

10.2						Amended and Restated Controlled Equity OfferingSM Sales Agreement, dated June 5, 2026, by and between Strive, Inc. and Cantor Fitzgerald & Co., Barclays Capital Inc., Clear Street LLC, The Benchmark Company, LLC, StoneX Financial Inc., B. Riley Securities, Inc., Maxim Group LLC and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on June 5, 2026).

10.3*						Strive, Inc. Short-Term Incentive Plan

10.4*						Form of Performance Stock Unit Agreement

31.1*						Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Principal Executive Officer.

31.2*						Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Principal Financial Officer.

32.1*						Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*						Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

101.SCH*						Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Document.

101.CAL*						Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*						Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*						Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE*						Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104						Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).


GRANTEE			STRIVE, INC.
___________________________________			___________________________________
Name: [FIRST LAST]			Name: Benjamin Pham
			Title: Chief Financial Officer


Dated: August 10, 2026			/s/ Matthew Cole
			Matthew Cole
			Chief Executive Officer